Organization Profile

You just read:

CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A

News provided by

CSL Behring

Jun 04, 2013, 09:01 ET